22 References 1. Virani, Salim S et al. “Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.” Circulation vol. 143,8 (2021): e254-e743. doi:10.1161/CIR.0000000000000950 2. Criqui, Michael H et al. “Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association.” Circulation vol. 144,9 (2021): e171-e191. doi:10.1161/CIR.0000000000001005 3. Gornik, Heather L et al. “2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/ SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation vol. 149,24 (2024): e1313-e1410. doi:10.1161/CIR.0000000000001251 4. Guédon, Alexis F et al. “Association of Lipoprotein(a) Levels With Incidence of Major Adverse Limb Events.” JAMA Network Open vol. 5,12 e2245720. 1 Dec. 2022, doi:10.1001/jamanetworkopen.2022.45720 5. Enkhmaa, Byambaa et al. “Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?.” Nutrients vol. 12,7 2024. 7 Jul. 2020, doi:10.3390/nu12072024 6. Arnett, Donna K et al. “2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.” Circulation vol. 140,11 (2019): e596-e646. doi:10.1161/ CIR.0000000000000678 7. Duarte Lau, Freddy, and Robert P Giugliano. “Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.” JAMA Cardiology vol. 7,7 (2022): 760-769. doi:10.1001/jamacardio.2022.0987 8. Tsimikas, Sotirios. “A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.” Journal of the American College of Cardiology vol. 69,6 (2017): 692-711. doi:10.1016/j.jacc.2016.11.042 9. Tipping, Robert W et al. “Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.” JAMA vol. 302,4 (2009): 412-23. doi:10.1001/jama.2009.1063 10. Patel, Aniruddh P et al. “Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank.” Arteriosclerosis, Thrombosis, and Vascular Biology vol. 41,1 (2021): 465-474. doi:10.1161/ATVBAHA.120.315291 11. Tsimikas, Sotirios, and Santica M Marcovina. “Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week.” Journal of the American College of Cardiology vol. 80,9 (2022): 934-946. doi:10.1016/j.jacc.2022.06.019 12. Reyes-Soffer, Gissette et al. “Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.” Arteriosclerosis, Thrombosis, and Vascular Biology vol. 42,1 (2022): e48-e60. doi:10.1161/ATV.0000000000000147 13. Enkhmaa B, Berglund L. Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis. 2022 May;349:53-62. doi: 10.1016/j. atherosclerosis.2022.04.006. PMID: 35606076; PMCID: PMC9549811. 14. Grundy, Scott M et al. “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/ AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.” Circulation vol. 139,25 (2019): e1082-e1143. doi:10.1161/CIR.0000000000000625 15. Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, Gill EA, Jacobson TA, Michos ED, Safarova MS, Soffer DE, Taub PR, Wilkinson MJ, Wilson DP, Ballantyne CM. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024 May-Jun;18(3):e308-e319. doi: 10.1016/j.jacl.2024.03.001 16. Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, Francis GA, Genest J, Grégoire J, Grover SA, Gupta M, Hegele RA, Lau D, Leiter LA, Leung AA, Lonn E, Mancini GBJ, Manjoo P, McPherson R, Ngui D, Piché ME, Poirier P, Sievenpiper J, Stone J, Ward R, Wray W. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021 Aug;37(8):1129-1150. doi: 10.1016/j.cjca.2021.03.016 17. Mach, Francois et al. 2019 ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal vol. 41, Issue 1, (2020). https://doi.org/10.1093/eurheartj/ehz455 18. Farzam K, Zubair M, Senthilkumaran S. Lipoprotein A. [Updated 2024 Feb 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK570621/ 19. Yanaka, Koji et al. “Relationship Between Lipoprotein(a) and Angiographic Severity of Femoropopliteal Lesions.” Journal of Atherosclerosis and Thrombosis vol. 28,5 (2021): 555-561. doi:10.5551/jat.56457 20. Kamstrup, Pia R. “Lipoprotein(a) and Cardiovascular Disease.” Clinical Chemistry vol. 67,1 (2021): 154-166. doi:10.1093/clinchem/hvaa247 21. Tomoi, Yusuke et al. “Impact of High Lipoprotein(a) Levels on Clinical Outcomes Following Peripheral Endovascular Therapy.” JACC. Cardiovascular Interventions vol. 15,14 (2022): 1466-1476. doi:10.1016/j. jcin.2022.05.050 22. Verwer, Maarten C et al. “High lipoprotein(a) is associated with major adverse limb events after femoral artery endarterectomy.” Atherosclerosis vol. 349 (2022): 196-203. doi:10.1016/j.atherosclerosis.2021.11.019 23. Golledge, Jonathan et al. “Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery Disease.” Journal of the American Heart Association vol. 9,6 (2020): e015355. doi:10.1161/JAHA.119.015355 24. Schwartz, Gregory G. et al. “Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.” JACC vol. 78, 5 (2021): doi/10.1016/j.jacc.2021.04.102 25. Poller, Wolfram C et al. “Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a).” Atherosclerosis. Supplements vol. 18 (2015): 187-93. doi:10.1016/j. atherosclerosissup.2015.02.032 26. Roeseler, Eberhard et al. “Lipoprotein Apheresis for Lipoprotein(a)- Associated Cardiovascular Disease: Prospective 5 Years of FollowUp and Apolipoprotein(a) Characterization.” Arteriosclerosis, Thrombosis, and Vascular Biology vol. 36,9 (2016): 2019-27. doi:10.1161/ ATVBAHA.116.307983 27. Leebmann, Josef et al. “Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.” Circulation vol. 128,24 (2013): 2567-76. doi:10.1161/ CIRCULATIONAHA.113.002432 28. Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc. 2019 Feb 19;8(4):e010932. doi: 10.1161/ JAHA.118.010932. PMID: 30755061; PMCID: PMC6405654. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405654/ 29. Bittner, Vera A et al. “Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.” Journal of the American College of Cardiology vol. 75,2 (2020): 133-144. doi:10.1016/j. jacc.2019.10.057 30. Ray, Kausik K et al. “Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.” European Heart Journal vol. 43,48 (2022): 5047-5057. doi:10.1093/eurheartj/ehac615 31. Franchini, Massimo et al. “Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review.” Blood transfusion = Trasfusione del sangue vol. 14,5 (2016): 413-8. doi:10.2450/2015.0163-15 32. O’Donoghue, Michelle L et al. “Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.” The New England Journal of Medicine vol. 387,20 (2022): 1855-1864. doi:10.1056/NEJMoa2211023 33. Nissen, Steven E et al. “Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.” JAMA vol. 327,17 (2022): 1679-1687. doi:10.1001/jama.2022.5050 34. Nissen, Steven E et al. “Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized DoseAscending Clinical Trial.” JAMA vol. 330,21 (2023): 2075-2083. doi:10.1001/ jama.2023.21835 35. Dennison Himmelfarb, et al. “Shared Decision-Making and Cardiovascular Health: A Scientific Statement From the American Heart Association.” Circulation vol. 148,11 (2023): 912-931. doi:10.1161/CIR.0000000000001162 36. Centers for Disease Control and Prevention. About Lipoprotein a. (2023). About Lipoprotein (a) | Heart Disease, Family Health History, and Familial Hypercholesterolemia | CDC
RkJQdWJsaXNoZXIy MjI2NjI=